For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge.

Kinase activity has not been detected for several CDK-related proteins, but they are still known as PFTK2, PCTK2 or CCRK, where 'K' stands for 'kinase'. Finally, most 'cyclins' do not cycle.

The partnership is expected to yield treatments that demonstrate efficacy and offer improved quality of life and tolerability ...

Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

AKT regulates the cell cycle by phosphorylating FoxO1 and decreasing its transcription of CDK inhibitors p21 and p27. AKT, protein kinase B; CDK, cyclin dependent kinase; FoxO1, forkhead box O1 ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...

human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors ...